Farxiga Switching Protocols: How to Switch From or To Dapagliflozin and Other SGLT2 Inhibitors

How Dapagliflozin Works: The Mechanism Behind the Switch Logic

Dapagliflozin blocks the SGLT2 transporter in the proximal renal tubule, preventing reabsorption of roughly 60 to 90 grams of glucose per day and causing it to be excreted in urine. That single mechanism explains why a class switch is pharmacologically clean: every approved SGLT2 inhibitor hits the same transporter, so switching is a receptor-level substitution rather than a pathway change.

SGLT2 vs. SGLT1: Why Selectivity Matters for Switching

Dapagliflozin has roughly 1,200-fold selectivity for SGLT2 over SGLT1 [1]. Canagliflozin, by contrast, has approximately 250-fold selectivity, giving it partial SGLT1 inhibition in the gut that marginally slows postprandial glucose absorption [2]. Empagliflozin sits at approximately 2,500-fold SGLT2 selectivity [3]. These differences are modest in clinical practice, but they mean canagliflozin carries a slightly higher risk of GI side effects and osmotic diarrhea during initiation or class switch.

Renal Hemodynamic Effects That Persist Across the Class

Beyond glycosuria, SGLT2 inhibitors reduce intraglomerular pressure by restoring tubuloglomerular feedback through increased sodium delivery to the macula densa. This effect is consistent across agents. A patient switching from empagliflozin 10 mg to dapagliflozin 10 mg will retain the same afferent arteriole pressure reduction within 24 to 48 hours of the first replacement dose, which is clinically relevant in CKD management [4].

Cardiorenal Benefits: Not Interchangeable Across Indications

The trials that proved organ protection used specific agents. DAPA-HF used dapagliflozin 10 mg; EMPEROR-Reduced used empagliflozin 10 mg. A prescriber switching a patient with HFrEF from empagliflozin to dapagliflozin is moving between two FDA-approved options for that indication. A switch from canagliflozin (approved for T2D and CKD in CREDENCE) to dapagliflozin for HFrEF is supported by mechanism but represents an off-label-to-on-label transition for HF, worth documenting [5].

SGLT2 Inhibitor Comparison: Where Dapagliflozin Sits in the Class

Understanding where dapagliflozin fits relative to its competitors helps clinicians choose the right direction when switching.

Approved Indications by Agent

| Agent | T2D | HFrEF | HFpEF | CKD | |---|---|---|---|---| | Dapagliflozin (Farxiga) | Yes | Yes | Yes | Yes | | Empagliflozin (Jardiance) | Yes | Yes | Yes | Yes | | Canagliflozin (Invokana) | Yes | No | No | Yes | | Ertugliflozin (Steglatro) | Yes | No | No | No |

Dapagliflozin and empagliflozin currently hold the broadest indication profiles in the class. If a patient on canagliflozin develops HFrEF, switching to dapagliflozin or empagliflozin is guideline-supported [6].

Key Key Trials by Agent

Dapagliflozin: DAPA-HF (N=4,744, NEJM 2019) showed a 26% relative risk reduction in the composite of worsening heart failure or cardiovascular death (hazard ratio 0.74, 95% CI 0.65 to 0.85, P<0.001) [7]. DAPA-CKD (N=4,304, NEJM 2020) showed a 39% reduction in the composite of sustained eGFR decline of 50% or more, end-stage kidney disease, or death from renal or cardiovascular causes (HR 0.61, 95% CI 0.51 to 0.72, P<0.001) [8].

Empagliflozin: EMPA-REG OUTCOME (N=7,020) demonstrated a 38% reduction in cardiovascular death in T2D patients with established CV disease [9]. EMPEROR-Reduced showed a 25% reduction in the composite of CV death or worsening HF [10].

Canagliflozin: CREDENCE (N=4,401) showed a 30% reduction in the composite renal endpoint in T2D with CKD (HR 0.70, P=0.00001) [11]. CANVAS showed a 14% reduction in MACE but raised concern about lower-limb amputation risk (HR 1.97 per 1,000 patient-years) [12].

Direct Switching Protocol: Step-by-Step

No pharmacokinetic washout is required when switching between SGLT2 inhibitors. The FDA label for dapagliflozin does not specify a transition interval, and no published trial has demonstrated an additive safety benefit to a gap period [13].

Step 1: Confirm the Indication and Dose

• For T2D: dapagliflozin 5 mg or 10 mg once daily (10 mg preferred for cardiorenal benefit)
• For HFrEF, HFpEF, or CKD: dapagliflozin 10 mg once daily, the dose used in all major trials

If the patient is coming from canagliflozin 100 mg (the lower T2D dose), match to dapagliflozin 10 mg. If coming from canagliflozin 300 mg (the higher dose used for added glycemic or renal effect), dapagliflozin 10 mg is still the ceiling dose, document the intentional de-escalation and monitor HbA1c at 12 weeks.

Step 2: Pre-Switch Lab Checklist

Order these before the first dapagliflozin dose:

1. eGFR, dapagliflozin 10 mg is contraindicated for the glycemic indication with eGFR <25 mL/min/1.73 m². For HF and CKD indications, it may be used at lower eGFR values with physician oversight per the 2021 FDA label update [13].
2. Serum potassium, SGLT2 inhibitors modestly raise potassium in advanced CKD; confirm K<5.5 mEq/L before switching.
3. Urine or serum ketones, if the patient reports nausea, vomiting, or unusual fatigue, rule out euglycemic DKA before the switch.
4. Blood pressure, SGLT2 inhibitors produce a 2 to 4 mmHg systolic reduction; patients on aggressive diuretic regimens may need dose adjustment.

Step 3: Execute the Same-Day Switch

Stop the prior SGLT2 inhibitor at the end of the current supply or on the morning the new prescription is filled. Start dapagliflozin the following morning. There is no clinical rationale for overlap, two SGLT2 inhibitors on the same day doubles tubular SGLT2 blockade without meaningful added benefit and increases volume depletion risk substantially.

Step 4: Post-Switch Monitoring

• HbA1c at 12 weeks to confirm glycemic equivalence (or non-inferiority if downsizing from canagliflozin 300 mg)
• eGFR at 4 weeks in CKD patients (an acute 10 to 15% dip in eGFR is expected and does not indicate harm; it reflects reduced intraglomerular pressure)
• Body weight at 4 weeks, dapagliflozin produces approximately 2 to 3 kg weight loss from glycosuria-driven caloric loss [8]
• Genital mycotic infection assessment at each visit; the class-wide risk is roughly 5 to 10% in women and 2 to 4% in men [13]

Switching to Dapagliflozin From Each Specific Agent

From Empagliflozin (Jardiance)

Empagliflozin 10 mg to dapagliflozin 10 mg is a 1:1 switch. Both agents are FDA-approved for T2D, HFrEF, HFpEF, and CKD. The EMPEROR-Reduced and DAPA-HF trials showed similar absolute risk reductions (approximately 5 percentage points in the composite endpoint) despite different populations, so clinical equivalence in HF management is supported [7, 10].

A patient may switch for formulary reasons, out-of-pocket cost, or because their prescriber's institution uses dapagliflozin as the preferred agent per institutional guidelines. No efficacy gap is expected.

From Canagliflozin (Invokana)

This switch is common when a T2D patient develops HFrEF, because canagliflozin lacks FDA approval for heart failure. The AHA/ACC 2022 Heart Failure Guidelines give SGLT2 inhibitors a Class I, Level of Evidence A recommendation for HFrEF regardless of diabetes status, but that recommendation is tied to agents with trial data in HF specifically [6].

One factor to monitor: canagliflozin carries a documented amputation signal (HR 1.97 in CANVAS) [12]. Patients who switch away from canagliflozin to dapagliflozin may see this risk attenuate, though no head-to-head trial has directly measured this transition.

From Ertugliflozin (Steglatro)

Ertugliflozin is approved only for T2D, with no cardiovascular outcome trial demonstrating MACE reduction or HF benefit. VERTIS-CV (N=8,246) did not show a significant reduction in MACE vs. Placebo [14]. A patient on ertugliflozin who develops HF or CKD progression should switch to dapagliflozin or empagliflozin, this is an indication upgrade, not just a formulary swap. Start dapagliflozin 10 mg the morning after the last ertugliflozin dose.

From Sotagliflozin (Inpefa)

Sotagliflozin (approved by the FDA in May 2023 for HF) is a dual SGLT1/SGLT2 inhibitor, making the mechanism broader than pure SGLT2 blockade [15]. Switching from sotagliflozin to dapagliflozin means losing SGLT1 inhibition. The SOLOIST-WHF trial (N=1,222) used sotagliflozin in recently hospitalized HF patients; no equivalent dapagliflozin trial in that acute setting exists [16]. Document the rationale clearly, typically formulary access or tolerability, and watch for GI symptom improvement post-switch, since dapagliflozin's higher SGLT2 selectivity produces less osmotic diarrhea.

Switching From Dapagliflozin to Another SGLT2 Inhibitor

The same direct-substitution logic applies in reverse. Common scenarios:

To empagliflozin: Insurance formulary pressure is the most frequent driver. A patient stable on dapagliflozin 10 mg for HFrEF transitions to empagliflozin 10 mg the next morning. No loading dose, no titration.

To canagliflozin: Rare in HF patients given the indication gap. May occur in patients without HF whose plan covers canagliflozin 100 mg preferentially. Monitor foot and lower-limb exam at each visit given the CANVAS amputation signal.

To ertugliflozin: Essentially never recommended for patients with HF or CKD given the absent outcome data. Acceptable only in uncomplicated T2D with no CV or renal disease.

Special Populations: Adjustments to the Standard Switch Protocol

CKD Patients

The 2022 KDIGO guidelines recommend SGLT2 inhibitors for patients with T2D and CKD with eGFR 20 to 45 mL/min/1.73 m², citing DAPA-CKD and CREDENCE [4]. For a CKD patient switching between agents, confirm eGFR within 30 days before the switch. An expected acute 10 to 15% eGFR dip post-initiation of any SGLT2 inhibitor should not prompt discontinuation unless eGFR drops below 20 mL/min/1.73 m² or the patient develops symptomatic volume depletion.

Heart Failure Patients on Loop Diuretics

Patients on furosemide 40 mg or more daily carry meaningful baseline volume depletion risk. SGLT2 inhibitors produce an additional natriuretic effect that compounds diuretic action. When switching in this population, consider reducing furosemide by 20 to 40% on the day of the switch if systolic blood pressure is below 110 mmHg or if the patient reports orthostasis. The DAPA-HF trial permitted concomitant diuretic use in 93% of participants, confirming the combination is safe with monitoring [7].

Type 1 Diabetes (Off-Label)

Dapagliflozin carries FDA approval for T2D, not T1D. Its use in T1D is off-label and carries a substantially higher DKA risk (roughly 2 to 4% annually vs. <0.1% in T2D) because patients have no endogenous insulin to suppress ketogenesis. The ADA Standards of Care 2024 note that SGLT2 inhibitors "may be considered" in selected T1D patients under specialist supervision with strong ketone monitoring [17]. Switching within the SGLT2 class in T1D follows the same same-day protocol, but ketone monitoring becomes mandatory.

Perioperative and Sick-Day Rules

The FDA safety communication from 2015 and 2016 advises holding SGLT2 inhibitors 3 to 4 days before elective surgery or during prolonged fasting, serious illness, or restricted oral intake [18]. This hold applies during a switch transition if the patient is acutely ill. Resume dapagliflozin, not the old agent, once the patient is eating normally and the precipitating illness has resolved.

Reasons Clinicians Switch SGLT2 Inhibitors

The decision to switch agents within a class is rarely pharmacological. In clinical practice, the drivers cluster into four categories:

1. Indication upgrade. A patient on ertugliflozin or canagliflozin develops HFrEF or significant CKD, requiring an agent with proven cardiorenal benefit in that condition.
2. Formulary or cost. Insurance tier changes are the single most common reason. All four agents carry list prices above $500 per month without insurance, and formulary positioning changes annually.
3. Tolerability. Genital mycotic infections affect 5 to 10% of women on any SGLT2 inhibitor [13], but individual agents may be tolerated differently. Canagliflozin's partial SGLT1 blockade produces more GI symptoms for some patients, prompting a switch to the more SGLT2-selective dapagliflozin.
4. Amputation risk concern. Clinicians managing patients with peripheral arterial disease may prefer dapagliflozin or empagliflozin over canagliflozin given the CANVAS signal, even though causality remains debated and subsequent meta-analyses have attenuated the concern [12].

The 2022 AHA/ACC Heart Failure Guidelines state: "In patients with HFrEF, SGLT2 inhibitors are recommended to reduce hospitalization for HF and CV mortality, irrespective of the presence or absence of type 2 diabetes." [6] That recommendation does not name a preferred agent, giving prescribers flexibility to select based on the four factors above.

Safety Signals Specific to Switching (Not Initiation)

Clinicians sometimes assume that a patient stable on one SGLT2 inhibitor will tolerate a switch without any adverse events. That assumption holds for most patients, but three risks deserve specific mention at the time of transition.

Euglycemic DKA

DKA risk from SGLT2 inhibitors is tied to class-wide SGLT2 blockade, not to any individual agent. Switching does not increase DKA risk if the patient is otherwise stable. The risk window for DKA is highest in the first 30 days of SGLT2 inhibitor therapy overall. A patient who has been on empagliflozin for 2 years and switches to dapagliflozin is not re-entering a high-risk initiation window. The FDA safety communication from 2015 identified DKA events across all approved SGLT2 inhibitors with blood glucose often below 250 mg/dL [18].

Urinary Tract Infections

The class produces 2 to 4% excess UTI risk compared to placebo [13]. At the time of a switch, patients should be screened for active UTI symptoms. Symptomatic UTI should be treated before starting the new agent.

Fournier's Gangrene

The FDA added a warning for necrotizing fasciitis of the perineum (Fournier's gangrene) to all SGLT2 inhibitor labels in 2018, based on 12 post-marketing cases [19]. The absolute risk is extremely low. The switch itself does not increase this risk, but the warning applies to dapagliflozin as it does to every agent in the class.

Dapagliflozin Drug Interactions That Affect Switching Decisions

Dapagliflozin is metabolized primarily by UGT1A9 glucuronidation with minimal CYP450 involvement, reducing the risk of pharmacokinetic drug interactions [13]. The drugs most relevant to a switching decision:

• Insulin and sulfonylureas: Switching to dapagliflozin from an SGLT2 inhibitor while already on insulin increases hypoglycemia risk slightly due to additive glucose lowering. No dose adjustment is required when switching between SGLT2 inhibitors on stable insulin, but consider a 10 to 20% insulin reduction if HbA1c is already near target.
• Rifampin: A UGT1A9 inducer that reduces dapagliflozin AUC by approximately 22%, potentially reducing efficacy [13]. If a patient switches to dapagliflozin while on rifampin, monitor HbA1c response at 12 weeks.
• Loop diuretics: Covered above. Volume monitoring is the key clinical action.

The FDA label for dapagliflozin (NDA 202293) lists no absolute contraindicated drug combinations beyond the class-level renal threshold [13].